Shorts

Why patients choose Break Wave over URS

Jenny N. Guo, MD, on key BPH takeaways from AUA 2026

Joy Maulik, CRNP, highlights LUGPA Advanced Practice Provider Forum

The UroOnc Minute: Patient selection for MDT in the PSMA-PET era

Archan Khandekar, MD, on the future for AI in urology

Praful Ravi, MB, BChir, MRCP, on residual disease detection using PSMA-PET

What BULLSEYE's PFS data should—and shouldn't—mean

Why Break Wave Lithotripsy is a game changer for stone care

Aleece Fosnight, MSPAS, PA-C, on what to tell patients about microplastics and bladder health

Louise Emmett, MD, PhD, MBChB, FRACP, on the potential role of 225Ac-PSMA-617 earlier in mCRPC

Lucia Nappi, MD, on the future for miR371 in testicular cancer

Joshua Lang, MD, MS, highlights emerging biomarker strategies in GU oncology

Integrating immunotherapy into newly diagnosed MIBC

Kari A.O. Tikkinen, MD, PhD, discusses tranexamic acid in urology

Nicole L. Miller, MD, FACS, on advances in evaluating and treating LUTS

Catherine A. Matthews, MD, FACS, shares takeaways from the INTIBIA Pivotal Trial

Michael S. Cookson, MD, on darolutamide’s safety profile

Jonathan D. Harper, MD, on increasing fluid intake to prevent recurrent stones

Nima Almassi, MD, on shared decision-making around bladder-preserving treatment options

Kathryn H. Gessner, MD, PhD, on the most exciting current developments in bladder cancer

Joshua J. Meeks, MD, PhD, on the need for recombinant BCG

Nicole L. Miller, MD, FACS, on what she tells patients after BPH treatment failure

Michael S. Cookson, MD, on what ARASEC adds to the treatment intensification discussion

Catherine A. Matthews, MD, FACS, on the U-POP & LUTD 2026 Global Consensus Conference

Hung-Jui (Ray) Tan, MD, MSHPM, on how urology can close the workforce gap in underserved areas

Boris Chertin, MD, and Raj S. Pruthi, MD, MHA, FACS, on the unique nature of NDV-01

James Nagarajah, MD, on the headline finding of BULLSEYE in HSPC

Savitha Krishnan, MD, on signs of prolapse urologists should watch for

Zach Feuer, MD, on the impact of wait times for prostate biopsy referral

María Natalia Gandur Quiroga, MD, MSc, discusses the evolution of immunotherapy in bladder cancer